MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
ConditionAdvanced Solid Tumor
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Bergonié
About this trial
Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752
Eligibility criteria
Qualifiers
Histologically confirmed solid tumor
IO-naïve patients (cohort A) OR patients with secondary resistance to PD1/PDL1 inhibitors (cohort B),
have to be diagnosed previously treated with PD-L1/PD-1 inhibitors (investigational or approved),
must have experienced initial clinical benefit (stable disease or better) from checkpoint inhibitor therapy for at least 4 months in which there was at least one interval scan prior to 4 months demonstrating no progression of disease.
Disqualifiers
Any anticancer treatment within 21 days or 5 half-lives (whichever is shorter) prior to start of study treatment,
Whole brain radiotherapy within 14 days prior to start of study treatment,
Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
Stereotactic radiosurgery within 7 days prior to start of study treatment,
Trial design
Treatments tested in this trial
- MEDI5752
Treatment groups
102 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov